Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.
Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.
Read publication: JAMA Dermatology
Related
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with mo...
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe pso...
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
0 Comments